Richmond Pharmacology

Executive Summary

Richmond Pharmacology is a UK-based clinical research organization (CRO) founded in 2001, specializing in early-phase clinical trials. It has conducted over 500 studies and established itself as a pioneer in gene editing, becoming the first CRO to administer an LNP CRISPR-Cas9 therapy to a human. The company focuses on providing faster, adaptive trial designs from First-in-Human (FIH) to Proof-of-Concept (POC). With a strong track record in early-phase development, Richmond Pharmacology is well-positioned to capitalize on the growing demand for specialized CRO services, particularly in gene editing and rare disease indications. However, as a private CRO, its growth is tied to client engagement and successful trial execution rather than internal pipeline catalysts.

Upcoming Catalysts (preview)

• TBDInitiation of a new CRISPR-Cas9 gene editing trial50% success
• TBDExpansion of facility or service capabilities60% success
• TBDStrategic partnership with a major biopharma company40% success